Treatment of acquired hemophilia by the Bonn-Malmö Protocol: Documentation of an in vivo immunomodulating concept

Blood

Volumn 105, Issue 6, 2005, Pages 2287-2293

  Zeitler, Heike ^a   Ulrich Merzenich, Gudrun ^b   Hess, Lothar ^b   Konsek, Eligius ^b   Unkrig, Christoph ^b   Walger, Peter ^b   Vetter, Hans ^b   Brackmann, Hans Hermann ^b  

^a UNIVERSITY OF BONN   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; BLOOD CLOTTING FACTOR 8 ANTIBODY; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; NOVO 7; PREDNISOLONE; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ACQUIRED HEMOPHILIA; ADULT; AGED; ALOPECIA; ANOREXIA; APHERESIS; ARTICLE; BLEEDING TENDENCY; BLOOD CLOTTING DISORDER; BONN MALMO PROTOCOL; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL PROTOCOL; FEMALE; FEVER; HAIR LOSS; HEMOPHILIA; HUMAN; IMMUNOADSORPTION; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; MALE; MORTALITY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; REMISSION; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 15244340408     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-05-1811     Document Type: Article

References (37)

1. Delgado J, Yuste V, Navarro F, Villar A. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol. 2003;121:21-35.
2. Green D, Lechner K. A survey of 215 non-haemophilic patients with inhibitors to factor VIII. Thromb Haemost. 1981;4:200-203.
3. Freiburghaus C. Extracorporeal Immunoadsorption. Lund, Sweden: BTJ Tryck AB; 1998.
4. Cohen AJ, Kessler CM. Acquired inhibitors. Baillières Clin Haematol. 1996;9:331-354.
5. Sallah S, Wan JY. Inhibitors against factor VIII in patients with cancer. Cancer. 2001;9:1067-1074.
6. Shastri KA, Ho C, Logue G. An acquired factor V inhibitor: clinical and laboratory features. J Med. 1999;30:357-366.
7. Largo R, Sigg P, Felten Av, Straub PW. Acquired factor IX inhibitor in a non-haemophilic patient with autoimmune disease. Br J Haematol. 1974;26:129-140.
8. Boggio LN, Green D. Acquired haemophilia. Rev Clin Exp Hematol. 2001;5:389-404.
9. Brackmann HH, Oldenburg J, Schwaab R. Immune tolerance for the treatment of factor VIII inhibitor-twenty years "Bonn protocol." Vox Sang. 1996;70:30-35.
10. Brackmann HH. Induced immunotolerance in factor VIII inhibitor patients. Prog Clin Biol Res. 1984;150:181-195.
11. Nemes L, Pitlik E. New protocol for immune tolerance induction in acquired haemophilia. Haematologica. 2000;85:64-78.
12. Green D, Rademaker AW, Briet E. A prospective randomized trial of prednisone and cyclophosphamide in the treatment of patients with factor VIII autoantibodies. Thromb Haemost. 1993;70:753-757.
13. Schwartz R, Gabriel D, Aledort L, Green D, Kessler C. Prospective study of treatment of acquired (autoimmune) factor VIII inhibitors with high dose intravenous gammaglobulin. Blood. 1995;86:797-804.
14. Grodreuil S, Navarro R, Qittet L et al. Acquired haemophilia in the elderly is a severe disease: report of five new cases. Haemophilia. 2001;7:428-432.
15. Sultan Y, Kazatchkine MD, Nydehgger U, Rossi F, Diederich G, Algiman M. Intravenous immunoglobulin in the treatment of spontaneously acquired factor VIII:C inhibitors. Am J Med. 1991;91:35-39.
16. Hess L, Zeitler H, Unkrig C, et al. Modified Bonn-Malmö Protocol (MBM-P). Haematologica. 2003;88:78-85.
17. Nilson IM, Freiburghaus C. Apheresis. Adv Exp Med Biol. 1995;386:175-184.
18. Giles AR, Verbruggen B, Roivard GE, Teitel J, Walker I, and the Association of Haemophilia Centre of Canada. A detailed comparison of the performance of the standard versus Nijmegen modification of the Bethesda assay in detecting factor VIII: inhibitors in the haemophilia a population of Canada. Thromb Haemost. 1998;79:872-875.
19. Shaffer LG, Phillips MD. Successful treatment of acquired hemophilia with oral immunosuppressive therapy. Ann Intern Med. 1997;127:206-209.
20. Bayer RL, Lichtman SM, Allen S, et al. Acquired factor VIII inhibitors-successful treatment with an oral outpatient regime. Am J Hematol. 1999;60:70-71.
21. Lian EC, Villar MJ, Noy LI, Ruiz-Dayao Z. Acquired factor VIII inhibitor treated with cyclophosphamid, vincristine and prednisone. Am J Hematol. 2002;69:294-295.
22. Söhngen D, Specker C, Bach D, et al. Acquired factor VIII inhibitors in nonhemophilic patients. Ann Hematol. 1997;74:89-93.
23. Fischer KG, Deschler B, Lübbert M. Acquired high-titre factor VIII inhibitor: fatal bleeding despite multimodal treatment including rituximab preceded by multiple plasmapheresis. Blood. 2003;101:3753-3754.
24. Saint-Remy JMR. B- and T-cell tolerance: from basic concepts to clinical practice. Haematologica. 2000;85:93-96.
25. Gilles JG, Vanzieleghem B, Saint-Remy JMR. Natural autoantibodies and anti-idiotypes. Semin Thromb Hemost. 2000;26:151-155.
26. Kazatchkine D, Lacroix-Desmazes S, Moreau A, Kaveri S. Idiotypic regulation of anti-factor VIII antibodies. Haematologica. 2000;85:97-99.
27. Brackmann HH, Schwaab R, Effenberg W. Antibodies to FVIII in hemophilia A patients. Vox Sang. 2000;78:187-190.
28. Sacco C, Patiarca F. Acute myeloid leukaemia following chronic low-dose cyclophosphamide for metastasic breast cancer. Tumori. 2001;87:101-103.
29. De Ridder D, van Poppel H, Demonty L, Gonsette R, Carton H, Baert L. Bladder cancer in patients with multiple sclerosis treated with cyclophosphamide. J Urol. 1998;159:1881-1884.
30. Henne T, Schmahl D. Occurrence of second primary malignancies in man-a second look. Cancer Treat Rep. 1985;69:415-424.
31. Kushner BH, Heller G, Cheung NK, et al. High risk of leukemia after short-term dose-intensive chemotherapy in-young patients with solid tumors. J Clin Oncol. 1998;16:3016-3020.
32. Stasi R, Brunetti M, Stipa E, Amadori S. Selective B cell-depletion with rituximab for the treatment of patients with acquired hemophilia. Blood. 2004;103:4424-4428.
33. Fischer KG, Deschler B, Lübbert M. Acquired high-titer factor VIII inhibitor: fatal bleeding despite multimodal treatment including rituximab preceded by multiple plasmapheresis. Blood. 2003;101:3753-3754.
34. Wiestner A, Cho HJ, Asch AS, Michelis MA, Zeller JA, Schechter GP. Rituximab in the treatment of acquired factor VIII inhibitors. Blood. 2002;100:3426-3428.
35. López-Grillo A, Hedrick E, Rashford M, Benyunes M. Rituximab: ongoing and future clinical development. Semin Oncol. 2002;29:105-112.
36. Cartron G, Watier H, Goley J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood. 2004;104:2635-2642.
37. von Depka M. Erworbene Hämophilie infolge Antikörperbildung gegen Faktor VIII. Hämostaseologie. 2003;23:28-35.